Connect with us
Cancer is Europe's second leading cause of death, expected to rank first by 2035, yet it receives only 7% of healthcare investment. Cases rose 60% from...
Technological advances in genomics, AI, and immunology are transforming breast cancer research, enabling personalized treatments and improved understanding of tumor biology. Key focuses include hereditary genetics,...
In addition to the drug against brain tumors, Laminar has two other drugs licensed in phase two: one, developed together with Ability Pharma, against pancreatic cancer,...
Pharma Mar has decided to liquidate its diagnostic subsidiary Genomics, as part of their strategy to focus on their core activity of drug development and marketing....
Pharma Mar has other programs in the clinical development phase for various types of solid tumors: lurbinectedin, and ecubectedin. Headquartered in Madrid, the group has subsidiaries...
Founded in 2015 by computer engineer and biomedicine PhD Oscar Flores and clinician and digital health consultant Miquel Àngel Bru, Genomcore operates in the management and...
Immuno-oncology and molecular oncology are two of Sanofi's most promising bets to tackle some of the most difficult-to-treat cancers. While immuno-oncology research is focused on finding...
Immunotherapy is being viewed as one of the alternatives of cancer cure.